Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study

What Was Tested

The paper reports a study of Apelin, published as a randomized controlled trial.

Despite treatment, patient outcomes remain poor and newer therapies are urgently needed.

Here, the researchers investigated the systemic and renal effects of apelin in CKD.

Who Took Part

The abstract describes 24 subjects taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Apelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the subjects nor the staff measuring them knew who was on Apelin, so expectations could not easily colour the readings.

Some subjects received a placebo instead of Apelin, giving a reference point.

In the crossover set-up each of the subjects took both Apelin and the comparison in turn, acting as their own control.

What Was Measured

Despite treatment, patient outcomes remain poor and newer therapies are urgently needed.

The co-primary endpoints were change in systemic vascular resistance index and renal blood flow.

The subject headings attached to it are Apelin, Blood Pressure, Cardiac Output, Glomerular Filtration Rate, Hemodynamics, Intercellular Signaling Peptides and Proteins and Kidney.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Apelin in 24 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2024 (Nature communications), a journal based in England.

More context: the Apelin compound page, all human trials.